Noni Maria, Kalogera Eleni, Xydia Athina, Paradeisis Georgios, Spyridopoulou Kalliopi, Zachariadou Levantia, Botsa Evanthia
First Department of Pediatrics, Medical School, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, 115 27 Athens, Greece.
Microbiology Department, "Aghia Sophia" Children's Hospital, 115 27 Athens, Greece.
Children (Basel). 2025 Mar 19;12(3):381. doi: 10.3390/children12030381.
The MeMed BV BV score is a novel, promising host-protein score, differentiating bacterial from viral infections, that combines the expression levels of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP-10), and C-reactive protein (CRP). The aim of our study was to determine its diagnostic accuracy in hospitalized febrile children. A prospective study was performed from December 2023 to April 2024 in two pediatric clinics at "Aghia Sophia" Children's Hospital, Athens, Greece. Patients > 3 months old, presenting with fever, clinical suspicion of acute infection, and symptoms onset up to 7 days prior were considered eligible. Patients with cancer, Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Tuberculosis (TB), and immunodeficiency were excluded. Two pediatricians reviewed the clinical, laboratory, microbiological, and radiological data and assigned the final diagnosis. The experts were blinded to the BV scores. One hundred and thirty-five patients were enrolled. The predominant medical condition was respiratory tract infection (59.3% lower, 26.7% upper). Twenty-nine (21.5%) patients were diagnosed with bacterial infections. The BV score demonstrated a sensitivity of 96.2%, specificity of 88.7%, and negative predictive value (NPV) of 98.9% for bacterial infections. Equivocal BV scores were reported in 8.9% of cases and were excluded from calculations. The area under the curve was 0.96 (95% CI: 0.93-0.99). A ROC curve analysis was performed, and the optimal cut-off score was estimated at 60, providing a sensitivity of 93.1%, specificity of 88.7%, and NPV of 97.9%. In our study population, the BV score showed high sensitivity and NPV in bacterial infection diagnosis. Further studies are needed to assess the possibility of replacing the "equivocal" range with a narrower one or a specific cut-off value.
MeMed BV BV评分是一种新颖且有前景的宿主蛋白评分,可区分细菌感染和病毒感染,它结合了肿瘤坏死因子相关凋亡诱导配体(TRAIL)、干扰素γ诱导蛋白10(IP-10)和C反应蛋白(CRP)的表达水平。我们研究的目的是确定其在住院发热儿童中的诊断准确性。2023年12月至2024年4月在希腊雅典“Aghia Sophia”儿童医院的两家儿科诊所进行了一项前瞻性研究。年龄大于3个月、出现发热、临床怀疑急性感染且症状出现时间在7天以内的患者被认为符合条件。患有癌症、人类免疫缺陷病毒(HIV)、乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)、结核病(TB)和免疫缺陷的患者被排除。两名儿科医生审查了临床、实验室、微生物学和放射学数据并做出最终诊断。专家们对BV评分不知情。共纳入135名患者。主要疾病是呼吸道感染(下呼吸道感染占59.3%,上呼吸道感染占26.7%)。29名(21.5%)患者被诊断为细菌感染。BV评分对细菌感染的敏感性为96.2%,特异性为88.7%,阴性预测值(NPV)为98.9%。8.9%的病例报告了模棱两可的BV评分,在计算中被排除。曲线下面积为0.96(95%可信区间:0.93 - 0.99)。进行了ROC曲线分析,估计最佳截断评分为60,敏感性为93.1%,特异性为88.7%,NPV为97.9%。在我们的研究人群中,BV评分在细菌感染诊断中显示出高敏感性和NPV。需要进一步研究以评估用更窄的范围或特定截断值取代“模棱两可”范围的可能性。